Curasight continues its glioblastoma trial following approval of updated protocol

2026-10-06 11:24:00

Curasight can resume enrolment in its phase I glioblastoma trial after regulators gave the go ahead for an amended protocol. With dosing back under way, the company holds to its timeline for topline data in H1 2027.

Read the full article at biostock.se:

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.